Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMWDNOK)

Drug Name
REVERSINE Drug Info
Synonyms
Reversine; 656820-32-5; 2-(4-Morpholinoanilino)-6-cyclohexylaminopurine; UNII-Z499CLJ023; CHEMBL188343; CHEBI:70723; ZFLJHSQHILSNCM-UHFFFAOYSA-N; Z499CLJ023; N~6~-Cyclohexyl-N~2~-(4-Morpholin-4-Ylphenyl)-9h-Purine-2,6-Diamine; IN1127; 9H-Purine-2,6-diamine,N6-cyclohexyl-N2-[4-(4-morpholinyl)phenyl]-; C21H27N7O; N6-cyclohexyl-N2-(4-morpholinophenyl)-7H-purine-2,6-diamine; N(6)-cyclohexyl-N(2)-[4-(morpholin-4-yl)phenyl]-9H-purine-2,6-diamine; 2vgo; Reversine(HPLC); AD5; AC1L4OI2; AC1Q4YB4; MLS006010275; SCHEMBL1800790
Cross-matching ID
PubChem CID
210332
ChEBI ID
CHEMBL188343
CAS Number
CAS 656820-32-5
TTD Drug ID
D00JMT

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid hormone biosynthesis 1.94 9.92e-3 43/61 (70.49%) AKR1C3;AKR1C2;AKR1C1;...
Ribosome 1.84 1.49e-2 113/158 (71.52%) RPL10A;RPS4Y1;RPL13;...
Ascorbate and aldarate metabolism 1.84 9.92e-3 15/30 (50%) ALDH2;UGT2B15;UGT2B17;...
Coronavirus disease 1.80 2.23e-2 215/232 (92.67%) CFD;AGTR1;MX2;...
Staphylococcus aureus infection 1.79 1.78e-2 72/95 (75.79%) CFD;KRT19;KRT15;...
Histidine metabolism 1.73 3.80e-2 16/22 (72.73%) MAOA;ALDH2;HNMT;...
Viral protein interaction with cytokine and cytokine re... 1.71 3.82e-2 84/100 (84%) CXCL14;CX3CL1;CCL19;...
Fatty acid degradation 1.70 3.97e-2 40/43 (93.02%) ADH1B;ALDH2;ACAA2;...
Graft-versus-host disease 1.69 4.08e-2 32/42 (76.19%) HLA-DQA1;KLRD1;HLA-DPB1;...
Ether lipid metabolism 1.69 3.87e-2 32/49 (65.31%) PLAAT3;PLPP2;ENPP2;...
DNA replication -1.84 3.53e-2 34/36 (94.44%) MCM2;POLE;PRIM2;...
Steroid biosynthesis -1.95 2.02e-2 19/20 (95%) NSDHL;FDFT1;SOAT1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H